AlphAIAlphAI — Financial news for AI agents
BenzingaNOV 203 min read$KTTA

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - Pasithea Therapeutics (NASDAQ:KTTA), Pasithea Therapeutics (NASDAQ:KTTAW)

-- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved stable disease and ...

Original reporting
Benzinga · Globe Newswire
Published Nov 20, 2025, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2025, 10:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$KTTA
Bullish
high confidence
Mentioned
$KTTA
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$KTTABullishHigh
01

Why it matters

The trial results may accelerate the company's development timeline and attract investor interest, potentially elevating stock price.

02

Market read

The news is highly relevant for biotech investors and analysts tracking oncology developments.

03

What to watch

Regulatory hurdles or delays in subsequent trial phases could negate initial optimism.

Relevance 6/10Timing: Immediate, as the news is recent and impactful

Background

Pasithea Therapeutics is developing PAS-004, a therapy targeting advanced cancers, with recent positive Phase 1 data indicating clinical activity.

Company-level read

Ticker impact

$KTTABullishHigh confidence
Context

The news pertains directly to Pasithea Therapeutics, listed under ticker KTTA, with positive clinical trial data indicating potential stock appreciation.

Expected impact

Moderate to significant short-term increase in stock price, contingent on further clinical validation.

Evidence & confidence

The announcement of positive trial data, including partial responses and a favorable safety profile, typically boosts investor confidence and stock valuation, especially for biotech firms with promising therapies.

Market effects

Sector

Potential positive impact on biotech and oncology sectors

Regional

Likely to influence U.S. biotech indices

Global

Limited, as the news pertains to a specific company's clinical trial data

Counterpoint

What could challenge this read

The positive data may already be priced in; upcoming trial phases could reveal setbacks, leading to volatility.

Key entities

  • Company
    Pasithea Therapeutics

    Biotech firm focusing on innovative cancer therapies.

  • Drug Candidate
    PAS-004

    Therapeutic agent demonstrating clinical activity in Phase 1 trials.

Read at source← All news

Related articles

OCT 23
$KTTAMedAI 8/10

Two people with advanced cancer remain on a trial drug for over 500 days, with stable disease.

Pasithea Therapeutics (KTTA) reported positive data from its Phase 1 trial of PAS-004, showing prolonged stable disease in four advanced cancer patients, including two on treatment for over 500 days. The drug demonstrated a favorable safety profile with no serious adverse events and a long half-life supporting chronic dosing. Data was presented at ESMO Congress 2026.

stocktitan.net2 min
JUN 2
$KTTAMedAI 9/10

Pasithea's PAS-004 Receives FDA Orphan Drug Designation In Treating AL. Sclerosis

Pasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.

rttnews.com3 min
OCT 23
$BMYMed

Bristol Myers Squibb Reports CAR T-Cell Therapy Data In Multiple Sclerosis

Bristol Myers Squibb (BMY) reported interim Phase 1 Breakfree-2 study results for its CAR T-cell therapy zolacabtagene autoleucel in 66 multiple sclerosis patients. 92% of progressive MS patients showed stable or improved disability. Safety issues included cytokine release syndrome in 42.4% of patients. BMY stock is down 2.26% at $61.56.

rttnews.com2 min